Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab interval extension and Ang-2 effects in neovascular AMD
jRCTs031240273Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of faricimab in exudative macular degeneration (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Primary endpoint (switch subjects) and Primary endpoint (naive subjects). Started Aug 2024; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCTs031240273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240273.